FDA authorizes platform that predicts COVID-19 complications

The FDA issued an emergency use authorization for CLEWICU, an artificial intelligence-based platform that identifies several COVID-19 complications hours before they occur, the manufacturer said in a press release.“CLEWICU is a subscription software service deployed on the cloud that provides each customer a unique setup that varies based on many factors like size, term and integration needs,” Mitch Steiner, chief commercial officer of CLEW, told Healio Primary Care.Gal Salomon, co-founder and CEO of CLEW, added that the company’s artificial intelligence-based algorithmsRead More

Share on facebook
Share on twitter
Share on linkedin